TME Pharma receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Substantially improved survival and progression-free survival under NOX-A12 treatment combination compared to matched st…
. 100% radiographic partial response rate achieved in patients on NOX-A12 + radiotherapy + bevacizumab, 83% with durab…
. Data show 83% of chemotherapy refractory patients achieved radiographic partial response All radiographic partial re…
Bei 90 % der Patienten kommt es zu einem Rückgang der Tumorgröße Bei 40 % der Patienten kommt es zu einem partiellen…
Les données principales de l’étude d'escalade de dose phase 1/2 GLORIA évaluant NOX-A12 dans le cancer du cerveau seront…
Full top-line results from dose escalation of NOX-A12 Phase 1/2 GLORIA trial in brain cancer to be presented at ASCO 202…
Vorstellung vollständiger Top-Line Ergebnisse aus der Dosissteigerung der Phase-1/2-GLORIA-Studie mit NOX-A12 zur Behand…
After receiving priority review in 2018, CIMZIA® (certolizumab pegol) is now approved in China for the treatment of Mode…
NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Kre…